Alliance A092104: A randomized phase 2/3 study of olaparib plus temozolomide versus investigator’s choice for the treatment of patients with advanced uterine leiomyosarcoma after progression on prior ...
Multicenter prospective validation of PanClaudinAI: An AI for predicting Claudin 18.2 from CT in pancreatic cancer. This is an ASCO Meeting Abstract from the 2026 ASCO Gastrointestinal Cancers ...
Funding will be used to establish the clinical utility of OneMap™, a proprietary artificial intelligence (AI) driven single cell transcriptomic oncology platform, to guide treatment decisions, patient ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results